NLRP3 and Thrombocytopenia: Intriguingly, selective NLRP3 inhibitors have been shown to ameliorate platelet defects associated with DV, suggesting that the NLRP3 inflammasome may be a novel target for the treatment of Dengue-associated thrombocytopenia [76].